BioWorld

RAF inhibitors described in Deciphera Pharmaceuticals patent

Deciphera Pharmaceuticals LLC has patented new serine/threonine-protein kinase B-raf (BRAF) and/or RAF proto-oncogene serine/threonine-protein kinase (RAF1; c-Raf) inhibitors reported to be useful for ...
Seeking Alpha

Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma

SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients ...
ascopubs.org

Phase I Clinical Trial Evaluating Safety, Tolerability, and Early Activity of Exarafenib (KIN-2787), a Highly Selective Pan-RAF Inhibitor, in BRAF-Altered Solid Tumors or NRAS ...

Chemoradiation and Image-Guided Brachytherapy Alone or in Combination With Protease Inhibitor (Nelfinavir Mesylate) in Stage III Cervical Cancer: Results From a Phase III Trial Exarafenib's maximal ...
ascopubs.org

Quest for Clinically Effective RAF Dimer Inhibitors

Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non–Small-Cell Lung Cancer The following represents ...
Seeking Alpha

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories

Kinnate has entered into an Asset Purchase Agreement (the “APA”) with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets. The transaction is in furtherance of ...